rais price de-
rais dcf-base pt base belief
mitral heart adjac significantli de-risk strongli posit
coapt result link show mitral repair could influenc hard
outcom thesi also depend ew lead share posit tavr
market like show acceler next year releas low
risk trial result drive increas convers surgic popul
model structur heart market tavr mitral/
coapt major de-risk event coapt trial link
optim medic therapi provid rigor proof mitral repair perhap
replac alter clinic cours patient moderate-sever
sever mitral regurgit registri data suggest mitral repair
benefit symptom statu perhap mortal link coapt
definit rct field need view mitra-fr provid
discord result patient select trial heavili bias toward
patient mild-moder mitral regurgit unlik benefit
repair believ coapt importantli de-risk ew mitral/tricuspid
opportun lower associ discount rate accordingli
readili convert surgic patient thesi also depend
ew retain share tavr market show acceler next
year releas low risk trial result compar tavr surgeri
prior analysi nation inpati sampl databas
distinguish tavr market growth stem recruit elderli
like get surgeri convers good surgic candid tavr link
show tavr market growth larg due
recruit elderli favor low risk result believ
surgic convers meaning acceler exit estim
readili convert surgic patient tavr market unit
could highli impact increas competit boston
scientif buy secondarili remain consider believ
ew sole focu structur heart associ steadi innov
buoyanc market support continu stock momentum
continu pg
tr target
valuat risk price target sum assign base busi
inclus tavr associ mitral/tricuspid adjac base busi dcf
assum ew tavr overal sale ex-mitral/tricuspid
unburden invest structur heart adjac presum oper margin
base busi thusli defin employ discount rate termin growth
rate presum develop non-thvt growth driver mitral tricuspid
consid termin valu contribut combin segment assum
market ew hold share associ oper margin point
time discount rate termin growth rate given larger patient size
mitral/tricuspid adjac interven trans-cathet learn tavr off-set
increas technical/clin uncertainti dont feel market assumpt year henc
unreason like take tavr year achiev sale trans-cathet mitral
sale alreadi total dont assign valu mitral/tricuspid posit cash flow
prior consider drag invest period princip risk
thesi includ over-estim address aortic mitral tricuspid preval pool
technical/clin uncertainti mitral/tricuspid heighten competit thvt higher
page
page
million except per share surgeri expens inc interest incom adjust analysisgross sg analysistot sale sale cc cc ex cc incl cc incl cardioband vasc forma corpor
edward lifesci corp focus technolog treat structur heart diseas
critic ill patient design develop manufactur market product treat cardiovascular
diseas product technolog categor three area surgic heart valv therapi
transcathet heart valv critic surgic heart valv therapi portfolio includ
tissu heart valv heart valv repair product surgic replac repair patient
heart valv transcathet heart valv portfolio includ technolog design treat heart
valv diseas use catheter-bas approach oppos open surgic techniqu critic
portfolio product includ pulmonari arteri cathet dispos pressur transduc
advanc monitor system found mile lowel edward
headquart irvin ca
invest thesi ew remain unchang princip driven share posit
tavr market believ exceed link similar size mitral/tricuspid
opportun circa continu market momentum could help allay concern held
investor regard size underli preval pool also feel cours
investor attent becom reliabl focus mitral/tricuspid adjac
preval us mitral/tricuspid patient versu aortic stenosi patient link thu
rate share buy
valuat risk
price target sum assign base busi inclus tavr
associ mitral/tricuspid adjac base busi dcf assum ew
tavr overal sale ex-mitral/tricuspid unburden invest structur
heart adjac presum oper margin base busi thusli defin
employ discount rate termin growth rate presum develop
non-thvt growth driver mitral tricuspid consid termin valu contribut
combin segment assum market ew hold share associ
oper margin point time discount rate termin growth rate given
larger patient size mitral/tricuspid adjac interven trans-cathet learn
tavr off-set increas technical/clin uncertainti dont feel market
assumpt year henc unreason like take tavr year achiev
sale trans-cathet mitral sale alreadi total dont assign valu
mitral/tricuspid posit cash flow prior consider drag invest
princip risk thesi includ over-estim address aortic mitral
tricuspid preval pool technical/clin uncertainti mitral/tricuspid heighten competit
thvt higher expect thvt price pressur
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
